Reports Q3 revenue $2.79B, consensus $890K. As of September 30, POINT had approximately $399.0M in cash, cash equivalents, and investments, which is anticipated to fund operations into 2026. “The founding mission of our company is to accelerate the discovery, development and global access to radiopharmaceuticals,” said CEO Joe McCann. “I view Lilly’s agreement to acquire POINT as validation of the uniqueness of our team, infrastructure and pipeline. Together, we can become a global radiopharmaceutical leader, executing on our mission and transforming lives touched by cancer.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNT:
- Largest borrow rate increases among liquid names
- POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
- Eli Lilly extends tender offer to acquire Point Biopharma for $12.50 per share
- PNT Earnings this Week: How Will it Perform?